Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Ajinomoto Bio-Pharma Services has announced the launch of AJILITY™, a flexible and agile drug product manufacturing platform.
read more
Wednesday, November 28, 2018
Ajinomoto Bio-Pharma Services presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective bioconjugation technology, AJICAP.
read more
Ajinomoto Bio-Pharma has announced the launch of AJILITY™, a flexible and agile drug product manufacturing platform.
read more
Ajinomoto Bio-Pharma Services has completed the acquisition of Granules OmniChem Private, purchasing the remaining 50 percent ownership interest from Granules India.
read more
Tuesday, January 10, 2023
Ajinomoto Co., Inc. announced a license agreement with Exelixis, Inc. to incorporate AJICAP®, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis’ antibody-drug conjugate (ADC) ...
read more
Tuesday, October 02, 2018
Ajinomoto Althea and OmniChem announced they are integrating their businesses and operations as a unified CDMO and changing their name to Ajinomoto Bio-Pharma Services.
read more
Thursday, December 10, 2015
Ajinomoto Althea, Inc. (“Althea”) recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs).
read more
Wednesday, October 14, 2015
Ajinomoto Althea, Inc. today announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs). The new facility is located in close proximity to ...
read more
Ajinomoto Althea, Inc. announced today it is expanding the capacity of its Fill and Finish operations through the addition of a second manufacturing shift.
read more
Thursday, August 24, 2017
Ajinomoto Althea, Inc. (“Althea”), a leading service provider of biopharmaceutical contract development and manufacturing drug programs, announces the installation and launch of a new high-performance sterile vial filling line.
read more
Ajinomoto Althea Inc., a leading provider of biotherapeutic contract development and manufacturing services, today announced that the United States Patent and Trademark Office has issued US Patent 9,310,379 covering methods to crystallize monoclonal ...
read more
Tuesday, September 19, 2017
Ajinomoto Althea will soon open a GMP production suite in its newly constructed HPP commercial manufacturing facility located in San Diego.
read more
Tuesday, January 28, 2014
Ajinomoto Althea, Inc., a leading Contract Manufacturing Organization providing development and manufacturing services for biotechnology and pharmaceutical companies, announced today its new product offering, Corynex®, to produce secreted, soluble, ...
read more
J. David Enloe, Jr., CEO of Ajinomoto Althea was awarded Most Admired CEO in 2017 by the San Diego Business Journal.
read more
Ajinomoto Althea is appointing Dr. Lori McDonald as Vice President of Compliance at Althea. Althea's contract manufacturing business continues to grow at a rapid rate driven by biotech companies outsourcing aseptic fill and finish parenteral ...
read more